You are here

PEG-MODIFIED ENZYMES FOR IN-VIVO DECON OF OP TOXINS

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: N/A
Agency Tracking Number: 1R43GM061460-01A1
Amount: $95,950.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2001
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
3636 BLVD OF THE ALLIES, STE B17
PITTSBURGH, PA 15213
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 KEITH LEJEUNE
 () -
Business Contact
Phone: (412) 209-7298
Email: KLEJEUNE@AGENTASE.COM
Research Institution
N/A
Abstract

DESCRIPTION ( Investigator's Abstract): Agentase, LLC seeks
Small Business Innovation Research funding to determine the feasibility of
using chemically modified enzymes for the treatment and prevention of
organophosphorus poisonings. Several known enzymes exhibit hydrolytic activity
on target organophosphorus compounds including nerve agent, chemical weapons
such as sarin and soman as well as many commercially available pesticides
including acute antigenicity, poor enzyme stability, and brief in-vivo
residence times. When one considers that annually 3 million cases of severe
poisoning and 220,000 deaths worldwide are associated with OP pesticides, there
are obviously unmet needs associated with their use. There is a clear need for
technology capable of protecting individuals from overexposure to OP compounds.
Successful Phase I research will provide proof-of-concept that chemical
modification of enzymes alleviates the primary consequences associated with
their in-vivo use. Modified OP hydrolyzing enzymes have potential utility as
medical treatments for exposed individuals as well as preventative security for
individuals at high risk of OP exposure. Such treatments have potential utility
at hospitals, agricultural sites employing OP pesticides, civil defense
treatment centers for chemical terrorism, and with the armed forces.
PROPOSED COMMERCIAL APPLICATION:
Enzymatic treatment for the protection of individuals under high risk of exposure to
organophosphorus compounds. The technology may also have utility as a medical
treatment for individuals contaminated with OP agents. It is potentially useful in the
treatment of carbamate and organophosphorus pesticide exposures.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government